Investment Thesis
ALUMIS is an early-stage pharmaceutical company with minimal revenue ($1.7M) and massive operating losses (-$98.4M), coupled with negative operating cash flow of -$87.1M. While the strong balance sheet ($567M equity, $63.9M cash) provides operational runway of 1-2 years, the company lacks demonstrated profitability or clear revenue trajectory from available fundamentals.
Strengths
- Strong balance sheet with $567M stockholders' equity and effectively zero debt
- Substantial cash reserves of $63.9M providing runway for continued R&D operations
- Excellent liquidity position with 7.51x current ratio limiting near-term financial distress risk
Risks
- Massive operating losses of -$98.4M against only $1.7M revenue indicates unsustainable burn rate unsupported by revenue
- Negative operating cash flow of -$87.1M will deplete reserves within 12-18 months if business model does not change
- No demonstrated commercialization path or profitability timeline visible from available financial data; company appears in early R&D phase with unproven pipeline
Key Metrics to Watch
- Quarterly revenue growth and clinical trial progression for lead pipeline candidates
- Monthly operating cash burn rate and projected runway remaining
- Gross margin evolution as company transitions from R&D to commercialization phase
Financial Metrics
Revenue
1.7M
Net Income
-93.1M
EPS (Diluted)
$-0.74
Free Cash Flow
-87.2M
Total Assets
671.6M
Cash
63.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-5,652.4%
Net Margin
-5,344.8%
ROE
-16.4%
ROA
-13.9%
FCF Margin
-5,011.3%
Balance Sheet & Liquidity
Current Ratio
7.51x
Quick Ratio
7.51x
Debt/Equity
0.00x
Debt/Assets
15.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:35:23.816809 |
Data as of: 2026-03-31 |
Powered by Claude AI